Ophthalmology
-
Randomized Controlled Trial Multicenter Study Comparative Study
One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.
To compare different doses and dosing regimens of Vascular Endothelial Growth Factor (VEGF) Trap-Eye with laser photocoagulation in eyes with diabetic macular edema (DME). ⋯ Significant gains in BCVA from baseline achieved at week 24 were maintained or improved at week 52 in all VEGF Trap-Eye groups. Vascular Endothelial Growth Factor Trap-Eye warrants further investigation for the treatment of DME.
-
Case Reports Multicenter Study
Atypical presentations of orbital cellulitis caused by methicillin-resistant Staphylococcus aureus.
To evaluate the epidemiologic and clinical features of orbital cellulitis caused by methicillin-resistant Staphylococcus aureus (MRSA). ⋯ The author(s) have no proprietary or commercial interest in any materials discussed in this article.
-
Randomized Controlled Trial Multicenter Study
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
To evaluate the efficacy and safety of intravitreal ranibizumab in diabetic macular edema (DME) patients. ⋯ Ranibizumab rapidly and sustainably improved vision, reduced the risk of further vision loss, and improved macular edema in patients with DME, with low rates of ocular and nonocular harm.
-
Randomized Controlled Trial Multicenter Study
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.
To evaluate the safety and efficacy of 1 or 2 treatments with dexamethasone intravitreal implant (DEX implant) over 12 months in eyes with macular edema owing to branch or central retinal vein occlusion (BRVO or CRVO). ⋯ Proprietary or commercial disclosure may be found after the references.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Retinopathy of prematurity in infants weighing less than 500 grams at birth enrolled in the early treatment for retinopathy of prematurity study.
To describe patient characteristics, classification, and onset of prethreshold retinopathy of prematurity (ROP), and ocular findings at 6 months corrected age in infants with birth weights <500 g who were enrolled in the Early Treatment for Retinopathy of Prematurity (ETROP) Study. ⋯ The author(s) have no proprietary or commercial interest in any materials discussed in this article.